Literature DB >> 10931658

ADME/PK as part of a rational approach to drug discovery.

.   

Abstract

Rational drug discovery requires an early appraisal of all factors impacting on the likely success of a drug candidate in the subsequent preclinical, clinical and commercial phases of drug development. The study of absorption, distribution, metabolism, excretion and pharmacokinetics (ADME/PK) has developed into a relatively mature discipline in drug discovery through the application of well-established in vitro and in vivo methodologies. The availability of improved analytical and automation technologies has dramatically increased our ability to dissect out the fundamentals of ADME/PK through the development of increasingly powerful in silico methods. This is fuelling a shift away from the traditional, empirical nature of ADME/PK towards a more rational, in cerebro approach to drug design.

Year:  2000        PMID: 10931658     DOI: 10.1016/s1359-6446(00)01540-3

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  20 in total

Review 1.  Early metabolism evaluation making traditional Chinese medicine effective and safe therapeutics.

Authors:  Yong Liu; Ling Yang
Journal:  J Zhejiang Univ Sci B       Date:  2006-02       Impact factor: 3.066

Review 2.  Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery.

Authors:  Mohammad S Alavijeh; Mansoor Chishty; M Zeeshan Qaiser; Alan M Palmer
Journal:  NeuroRx       Date:  2005-10

3.  Drug development: Lessons from nature.

Authors:  Sunil Mathur; Clare Hoskins
Journal:  Biomed Rep       Date:  2017-05-09

Review 4.  The genetics of drug efficacy: opportunities and challenges.

Authors:  Matthew R Nelson; Toby Johnson; Liling Warren; Arlene R Hughes; Stephanie L Chissoe; Chun-Fang Xu; Dawn M Waterworth
Journal:  Nat Rev Genet       Date:  2016-03-14       Impact factor: 53.242

5.  Modeling and Simulation of Intracellular Drug Transport and Disposition Pathways with Virtual Cell.

Authors:  Jason Baik; Gus R Rosania
Journal:  J Pharm Pharmacol (Los Angel)       Date:  2013-09-13

6.  Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents.

Authors:  Nageshwar R Budha; Nitin Mehrotra; Rajendra Tangallapally; Jianjun Qi; Antwan J Daniels; Richard E Lee; Bernd Meibohm
Journal:  AAPS J       Date:  2008-03-14       Impact factor: 4.009

7.  Decoration of dihydropyrimidine and dihydropyridine scaffolds with sugars via Biginelli and Hantzsch multicomponent reactions: an efficient entry to a collection of artificial nucleosides.

Authors:  Alessandro Dondoni; Alessandro Massi
Journal:  Mol Divers       Date:  2003       Impact factor: 2.943

8.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034.

Authors:  K-C Cheng; Walter A Korfmacher; Ronald E White; F George Njoroge
Journal:  Perspect Medicin Chem       Date:  2007-06-26

Review 9.  Discovery and resupply of pharmacologically active plant-derived natural products: A review.

Authors:  Atanas G Atanasov; Birgit Waltenberger; Eva-Maria Pferschy-Wenzig; Thomas Linder; Christoph Wawrosch; Pavel Uhrin; Veronika Temml; Limei Wang; Stefan Schwaiger; Elke H Heiss; Judith M Rollinger; Daniela Schuster; Johannes M Breuss; Valery Bochkov; Marko D Mihovilovic; Brigitte Kopp; Rudolf Bauer; Verena M Dirsch; Hermann Stuppner
Journal:  Biotechnol Adv       Date:  2015-08-15       Impact factor: 14.227

10.  A Validated LC-MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation.

Authors:  Mohamed W Attwa; Hany W Darwish; Nasser S Al-Shakliah; Adnan A Kadi
Journal:  Molecules       Date:  2021-05-05       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.